Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31176253 | 0.82 | MAP2K4 (0.54) | CYP2A6MKNK1MKNK2TRPV1PIM1 | |
| SCHEMBL31174411 | 0.81 | CYP2C9 (0.52) | CYP2A6 | |
| SCHEMBL29933950 | 0.78 | MKNK1 (0.51) | CYP2A6MKNK1MKNK2SIRT2SIRT1 | |
| SCHEMBL5918438 | 0.76 | CYP2A6 (0.45) | CYP2A6MKNK1MKNK2TRPV1 | |
| SCHEMBL4973059 | 0.76 | CYP2A6 (0.45) | CYP2A6MKNK1MKNK2TRPV1 | |
| SCHEMBL30108236 | 0.75 | MKNK1 (0.77) | CYP2A6MKNK1MKNK2F7F3 | |
| SCHEMBL13188346 | 0.75 | MKNK1 (0.77) | CYP2A6MKNK1MKNK2F7F3 | |
| SCHEMBL17515109 | 0.75 | CYP2A6 (0.46) | CYP2A6MKNK1MKNK2TRPV1 | |
| SCHEMBL31301228 | 0.75 | CHEK2 (0.59) | CYP2A6MKNK1MKNK2F7F3 | |
| SCHEMBL28334001 | 0.75 | CHEK2 (0.59) | CYP2A6MKNK1MKNK2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | CYP2A6 3050/4885MKNK1 635/4885MKNK2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.